Cargando…
PB1997: DARATUMUMAB, LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE FOR TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: OUTCOME AND SAFETY PROFILE FROM A REAL-WORLD SINGLE CENTER EXPERIENCE
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429541/ http://dx.doi.org/10.1097/01.HS9.0000850820.70181.23 |
| _version_ | 1784779476960280576 |
|---|---|
| author | Elsabah, H. Kassem, N. Gulied, A. Taha, R. Elomri, H. Cherif, H. |
| author_facet | Elsabah, H. Kassem, N. Gulied, A. Taha, R. Elomri, H. Cherif, H. |
| author_sort | Elsabah, H. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9429541 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94295412022-08-31 PB1997: DARATUMUMAB, LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE FOR TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: OUTCOME AND SAFETY PROFILE FROM A REAL-WORLD SINGLE CENTER EXPERIENCE Elsabah, H. Kassem, N. Gulied, A. Taha, R. Elomri, H. Cherif, H. Hemasphere Publication Only Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9429541/ http://dx.doi.org/10.1097/01.HS9.0000850820.70181.23 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Publication Only Elsabah, H. Kassem, N. Gulied, A. Taha, R. Elomri, H. Cherif, H. PB1997: DARATUMUMAB, LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE FOR TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: OUTCOME AND SAFETY PROFILE FROM A REAL-WORLD SINGLE CENTER EXPERIENCE |
| title | PB1997: DARATUMUMAB, LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE FOR TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: OUTCOME AND SAFETY PROFILE FROM A REAL-WORLD SINGLE CENTER EXPERIENCE |
| title_full | PB1997: DARATUMUMAB, LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE FOR TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: OUTCOME AND SAFETY PROFILE FROM A REAL-WORLD SINGLE CENTER EXPERIENCE |
| title_fullStr | PB1997: DARATUMUMAB, LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE FOR TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: OUTCOME AND SAFETY PROFILE FROM A REAL-WORLD SINGLE CENTER EXPERIENCE |
| title_full_unstemmed | PB1997: DARATUMUMAB, LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE FOR TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: OUTCOME AND SAFETY PROFILE FROM A REAL-WORLD SINGLE CENTER EXPERIENCE |
| title_short | PB1997: DARATUMUMAB, LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE FOR TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: OUTCOME AND SAFETY PROFILE FROM A REAL-WORLD SINGLE CENTER EXPERIENCE |
| title_sort | pb1997: daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: outcome and safety profile from a real-world single center experience |
| topic | Publication Only |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429541/ http://dx.doi.org/10.1097/01.HS9.0000850820.70181.23 |
| work_keys_str_mv | AT elsabahh pb1997daratumumablenalidomidebortezomibanddexamethasonefortransplanteligiblenewlydiagnosedmultiplemyelomaoutcomeandsafetyprofilefromarealworldsinglecenterexperience AT kassemn pb1997daratumumablenalidomidebortezomibanddexamethasonefortransplanteligiblenewlydiagnosedmultiplemyelomaoutcomeandsafetyprofilefromarealworldsinglecenterexperience AT gulieda pb1997daratumumablenalidomidebortezomibanddexamethasonefortransplanteligiblenewlydiagnosedmultiplemyelomaoutcomeandsafetyprofilefromarealworldsinglecenterexperience AT tahar pb1997daratumumablenalidomidebortezomibanddexamethasonefortransplanteligiblenewlydiagnosedmultiplemyelomaoutcomeandsafetyprofilefromarealworldsinglecenterexperience AT elomrih pb1997daratumumablenalidomidebortezomibanddexamethasonefortransplanteligiblenewlydiagnosedmultiplemyelomaoutcomeandsafetyprofilefromarealworldsinglecenterexperience AT cherifh pb1997daratumumablenalidomidebortezomibanddexamethasonefortransplanteligiblenewlydiagnosedmultiplemyelomaoutcomeandsafetyprofilefromarealworldsinglecenterexperience |